NCT06956092View on ClinicalTrials.gov

Glofitamab for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 30, 2025

Primary Completion Date

June 30, 2028

Study Completion Date

December 31, 2028

Conditions
B Cell Lymphoma (BCL)
Interventions
BIOLOGICAL

Glofitamab treatment

eceive Glofitamab treatment as per the instructions in the package insert.

Trial Locations (1)

450052

The First Affiliated Hospital of Zhengzhou University, Department of Oncology, Zhengzhou

All Listed Sponsors
lead

Zhengzhou University

OTHER